There are about 2118 clinical studies being (or have been) conducted in Malaysia. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
Previous studies confirmed that MARPE (Mini-screw Assisted Rapid Palatal Expansion) technique resulted in transverse skeletal expansion without the undesired dentoalveolar compensations or drawbacks. It also resulted in widening of the nasal cavity and zygomatic bone. ALT-RAMEC (Alternate Rapid Maxillary Expansion and Constriction) in literature proved to be advantageous over conventional RME in producing subluxation and sutural displacement to facilitate maxillary protraction in skeletal class III growing patients.The current study investigates the efficacy of a combination of MARPE/ ALT-RAMEC techniques to expand the maxilla in adult cases of transverse maxillary deficiency. It compares the proportion of success cases in patients who are treated with MARPE/ ALT-RAMEC to those treated using MARPE (conventional). It also describes the circum-maxillary sutural displacement in patients treated with both techniques, it hypothesizes that it will result in transverse skeletal expansion as well as sutural subluxation and displacement in young adult ages, which may be a sign of hope in the treatment of antero-posterior deficiency in adults without resorting to surgery. It also will describe the dento-skeletal changes (the amount of dental tipping) and the respiratory changes that occurred after applying the two different expansion techniques. It will also compare clinically, the changes occur gingivally (Gingival recession and Pocket depths) between pre-treatment and post-expansion periods.
The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).
A prospective, randomized, controlled study of Algeness® DF 3.5% Deep Volumizing Filler comparing to Juvéderm Voluma to correct midface volume loss.
This is open-label, randomized, multicentre study to compare the efficacy and safety of the 8-week versus 12-week of SOF-RVD combination treatment for non-cirrhotic chronic hepatitis C patients. All the recruited subjects will receive the treatment accordingly and be followed up for 24 weeks following the completion of treatment.
A randomized controlled trial will be used to determine the effectiveness of ST-NEPCO. The study will involve obese children aged 7 to 11 years old. Participants will be assigned randomly to either the intervention or control group. The intervention group will receive counselling from the researcher based on ST-NEPCO, meanwhile the control group will receive counseling from dietitians based on the routine care for the management of childhood obesity. The study will be conducted for duration of 24 weeks. The individual counseling session will be held once a month for each participant during the weekend.
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
60 samples are take to determine the effects of topical insulin on tear inflammatory mediators interleukin 1a, interleukin 6 and matrix metalloprotenase 9 in diabetics with dry eye disease.
The purpose of this study is to assess immune response of end stage renal failure patients after Covid 19 vaccination
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead. The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)